About
Atomo Diagnostics is an Australian medical device company that designs, develops, manufactures, and commercializes integrated rapid diagnostic test devices for global markets. Founded in 2010 by John Kelly, the company aims to create user-friendly diagnostic solutions that enhance usability and reduce errors for both healthcare professionals and consumers. The flagship technology platform, Pascal, simplifies rapid diagnostic testing, making it more reliable than traditional multi-component kits. Atomo offers a range of products, including HIV rapid tests, syphilis diagnostic tests, pregnancy tests, and COVID-19 rapid antibody tests. The company also provides custom OEM devices for various diagnostic applications, supporting the detection of infectious diseases and chronic conditions. Atomo serves a diverse customer base, including healthcare professionals, consumers, and public health organizations. The company is committed to improving diagnostic accuracy and accessibility, aligning with trends in telemedicine and consumer health. Atomo Diagnostics went public on the Australian Securities Exchange in April 2020, raising $30 million to further its mission of transforming diagnostics.
Technologies
Keywords
Company Information
-
Employees 30
-
Founded 2010
-
Annual Revenue $2479000
-
Total Funding $15442635
Location
Leichhardt, New South Wales, Australia, 2040
